Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 475 - Heterocyclic compounds containing pteridine ring systems
Patents for C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
11/2003
11/27/2003WO2003097647A1 Vitamin-mitomycin conjugates
11/27/2003WO2003024899A3 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
11/27/2003US20030220268 New phenylalanine derivatives
11/19/2003CN1456561A Preparations of leucovorin and its carbonates
11/13/2003US20030211079 Immobilization with polyoxyethylene glycol; adjust circulation half-life
11/06/2003WO2003060073A3 An in vivo protein screen based on enzyme-assisted chemically induced dimerization ('cid')
11/06/2003US20030208069 Method for producing 8-methoxy-quinoline carboxylic acids
10/2003
10/30/2003WO2003089416A1 Substituted pyrimidine-2,4(1h,3h)-diones for use as matrix metalloproteinase (mmp) inhibitors
10/29/2003EP1357114A1 Substituted pyrimidin-2,4(1H,3H)-diones as inhibitors of Matrix Metalloproteinases (MMP)
10/28/2003US6638926 Pyrazole compounds useful as protein kinase inhibitors
10/23/2003WO2003002064A3 Fused pyrimidine dhfr inhibitors as antibacterials
10/23/2003US20030199526 Pyrimidine-based compounds useful as GSK-3 inhibitors
10/23/2003US20030199511 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine
10/22/2003EP0908182B1 Preventives or remedies for diseases induced by hypofunction of nitric oxide synthase (nos)
10/15/2003EP1259508B1 Novel biarylcarboxamides
10/15/2003CN1124136C Drug containing methotrexate derivative
10/09/2003US20030191091 Use of riboflavin and flavin derivatives as chitinase inhibitors
10/02/2003WO2003080063A1 PREVENTIVES OR REMEDIES FOR DISEAES CAUSED BY eNOS EXPRESSION
10/02/2003US20030187026 Antiproliferative agents
10/02/2003CA2451516A1 Agent for preventing or treating diseases caused by enos expression
09/2003
09/25/2003US20030181635 Process for coupling amino acids to an antifolate scaffold
09/25/2003US20030181470 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors
09/24/2003EP1259512B1 Pteridine compounds for the treatment of psoriasis
09/18/2003WO2003075935A1 Drugs containing riboflavin-type compounds
09/18/2003WO2002062750A9 Cannabinoid receptor ligands
09/18/2003US20030176670 Multivalent macrolide antibiotics
09/18/2003US20030176436 For therapy and prophylaxis of bacterial infections, or their use as antiseptics, sterilizants, or disinfectants
09/17/2003EP0909184B1 Targeted drug delivery using sulfonamide derivatives
09/11/2003US20030171376 Methotrexate derivatives
09/04/2003US20030166798 Mixtures of condensation polymers comprising organonitrogen or organosulfur polymers and curing agents, having preferential binding, used for analysis, separation and resolution of racemic mixtures
09/04/2003US20030165928 Susceptibility to bone damage
09/03/2003CN1439641A Anti-cancer chemicals of methotrexate derivatives and their uses in pharmaceutical science
09/02/2003US6613767 Stable aqueous folinate solution
09/02/2003US6613367 Complete nutrition of infants products are characterized by the type and amount of protein and carbohydrate and the increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents. These products improve feelings
08/2003
08/27/2003CN1438899A Ethylenedicysteine (EC)-drug conjugates
08/27/2003CN1119346C Benzothiadiaxoles and derivatives
08/21/2003WO2003001887A3 Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors
08/21/2003US20030158197 Certain alkylene diamine-substituted heterocycles
08/20/2003EP1165566B1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
08/14/2003WO2003002713A3 Antibodies to opgl
08/14/2003US20030153544 Fatty acid derivatives
08/13/2003CN1117752C Method for purifying and crystallizing vitamin B2
08/12/2003US6605299 Releasable linkage and compositions containing same
08/07/2003US20030148991 Use of at least one lipoic acid, of a physiologically acceptable derivative and/or salt thereof and at least one C1 donor for producing formulation for C1 donor-assisted therapy of central nervous system disorders
08/05/2003CA2121351C The resolution of 5-methyltetrahydrofolic acid
07/2003
07/31/2003WO2003062240A1 Pteridine derivatives, method for the production thereof, and use thereof
07/31/2003WO2003062239A1 (6s)-5,6,7,8-tetrahydrofolic acid production process
07/31/2003US20030143304 Human and animal nutrition and dietary supplementation
07/31/2003CA2511238A1 Pteridine derivatives, method for the production thereof, and use thereof
07/30/2003EP1330440A1 Agent which inactivates pathogens, comprising an element that bonds with nucleic acids and the use thereof
07/30/2003CN1433312A Barbituric acid analogs as therapeutic agents
07/24/2003WO2003060073A2 An in vivo protein screen based on enzyme-assisted chemically induced dimerization ('cid')
07/24/2003US20030139388 Antiinflammatory agents; osteoporosis
07/24/2003US20030138785 Pteridinyl-based dimer catalyzes competitive bonding between fusion proteins (transglutaminases) on separate substrates, which activates expression of reporter gene (beta-lactamase)
07/23/2003EP1328319A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases
07/22/2003US6596721 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98%
07/10/2003US20030130286 Antiproliferative agents; anticancer agents; central nervous system disorders; antiarthritic agents
07/10/2003US20030130236 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
07/09/2003EP0190315B2 Dehydrated liposomes
07/02/2003EP1322161A1 Use of riboflavin and flavin derivatives as chitinase inhibitors
06/2003
06/26/2003WO2003051366A2 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
06/26/2003CA2470214A1 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
06/25/2003CN1426301A Compositions for treatment and prevention of cardiovascular diseases
06/25/2003CN1112363C Bicyclic pyrimidine derivatives and their use as anti-coagulants
06/19/2003WO2003049739A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/19/2003US20030114671 Corticotropin releasing factor antagonists
06/19/2003CA2469316A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/18/2003EP1319663A1 Antidepressant folic -, folinic- and glutamic-acid lithium salts
06/18/2003EP1318997A1 Pyrazole compounds useful as protein kinase inhibitors
06/18/2003EP1318814A2 Triazole compounds useful as protein kinase inhibitors
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/05/2003US20030105102 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity
06/04/2003CN1110569C Riboflavin-production process with micro-organisms of modified isocitratlyase activity
06/03/2003US6573252 Therapy and prevention of bony disorders; improved gastrointestinal tolerability
05/2003
05/22/2003US20030096858 The parent drug compound is modified by forming one or more of predetermined chemical arrangement within parent drug structure for programming specific course and rate of metabolism for drug that leads to inactive nontoxic metabolite
05/22/2003US20030096844 Cannabinoid receptor ligands
05/22/2003US20030095992 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots
05/21/2003CN1418879A Process for preparing 8-methoxy-quinolone
05/20/2003US6566509 Compound for use as bactericide
05/15/2003WO2003039552A1 Combination of pde4 or pde3/4 inhibitor and an anti-rheumatic drug
05/15/2003US20030092706 Mixtures of phosphodiesterase inhibitor and antiarthritic agents; bioavailability, side effect reduction
05/13/2003US6562969 Ricin inhibitors and methods for use thereof
05/13/2003US6562819 Compounds for inhibition of ceramide-mediated signal transduction
05/13/2003CA2021467C Heterocyclically substituted sulfonylureas, process for their preparation, and their use as herbicides or plant growth regulators
05/06/2003US6559149 Methotrexate derivatives
05/02/2003EP1305026A2 Barbituric acid analogs as therapeutic agents
04/2003
04/24/2003US20030078166 Pyrazole compounds useful as protein kinase inhibitors
04/23/2003EP1303641A2 Method for recovery of copper from sulfidic ore materials using super-fine grinding and medium temperature pressure leaching
04/16/2003EP0922045B1 Bicyclic pyrimidine derivatives and their use as anti-coagulants
04/03/2003US20030064993 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
04/03/2003US20030064332 Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
03/2003
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024899A2 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
03/20/2003US20030055250 Pteridine compounds for the treatment of psoriasis
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
1 ... 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 ... 28